Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123719132 | 12371913 | 2 | F | 2014 | 20160818 | 20160516 | 20160901 | EXP | US-ACORDA-ACO_123754_2016 | ACORDA | 62.28 | YR | F | Y | 0.00000 | 20160901 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 123719132 | 12371913 | 1 | PS | AMPYRA | DALFAMPRIDINE | 1 | Oral | 10 MG, BID | 22250 | 10 | MG | TABLET | BID | ||||||
| 123719132 | 12371913 | 2 | C | BETASERON | INTERFERON BETA-1B | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 123719132 | 12371913 | 1 | Gait disturbance |
| 123719132 | 12371913 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 123719132 | 12371913 | DE |
| 123719132 | 12371913 | HO |
| 123719132 | 12371913 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 123719132 | 12371913 | Brain cancer metastatic | |
| 123719132 | 12371913 | Cerebrovascular accident | |
| 123719132 | 12371913 | Lung carcinoma cell type unspecified stage IV | |
| 123719132 | 12371913 | Multiple sclerosis relapse |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |